Abstract:Background Olaparib targets the DNA repair pathways and has revolutionized the management of metastatic castration resistant prostate cancer (mCRPC). Treatment with the drug should be guided by genetic testing; however, published economic evaluations did not consider olaparib and genetic testing as codependent technologies. This study aims to assess the cost-effectiveness of BRCA germline testing to inform olaparib treatment in mCRPC. Methods We conducted a cost-utility analysis of germline BRCA testing-guided olaparib treatment compared to standard care without testing from an Australian health payer perspective. The analysis applied a decision tree to indicate the germline testing or no testing strategy. A Markov multi-state transition approach was used for patients within each strategy. The model had a time horizon of 5 years. Costs and outcomes were discounted at an annual rate of 5 percent. Decision uncertainty was characterized using probabilistic and scenario analyses. Results Compared to standard care, BRCA testing-guided olaparib treatment was associated with an incremental cost of AU 143,613 per QALY. The probability of BRCA testing-guided treatment being cost effective at a willingness-to-pay threshold of AU$100,000 per QALY was around 2 percent; however, the likelihood for cost-effectiveness increased to 66 percent if the price of olaparib was reduced by 30 percent. Conclusion This is the first study to evaluate germline genetic testing and olaparib treatment as codependent technologies in mCRPC. Genetic testing-guided olaparib treatment may be cost-effective with significant discounts on olaparib pricing.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the economic cost - effectiveness of olaparib treatment guided by germline BRCA testing compared to standard care in patients with metastatic castration - resistant prostate cancer (mCRPC). Specifically, the study aims to evaluate the cost - effectiveness of BRCA germline testing and olaparib treatment as an interdependent technology combination, an aspect that has not been fully considered in previous studies. The study specifically focuses on the cost - effectiveness analysis of this testing and treatment strategy from the perspective of Australian healthcare payers, as well as the impact of different parameter changes on the results. ### Research Background - **Disease Background**: Prostate cancer is the most common non - skin cancer among Australian men and the second leading cause of cancer - related deaths. Approximately 3,568 prostate cancer deaths occurred in 2020. Approximately 4.6% to 17% of prostate cancer patients have germline DNA repair gene mutations, among which BRCA1 and BRCA2 mutations are particularly common. - **Treatment Background**: Olaparib is a drug targeting the homologous DNA repair pathway and has been proven to have significant efficacy in mCRPC patients. However, treatment decisions should be based on genetic testing results, and previous economic evaluation studies have not fully considered the interdependence between olaparib and genetic testing. ### Research Objectives - **Primary Objective**: To evaluate the cost - effectiveness of olaparib treatment guided by germline BRCA testing compared to standard care in mCRPC patients. - **Secondary Objective**: To explore the impact of changes in different parameters (such as BRCA mutation rate, olaparib price, etc.) on the incremental cost - effectiveness ratio (ICER). ### Methods - **Model Description**: The study uses decision - tree and Markov multi - state transition models to conduct cost - utility analysis from the perspective of Australian healthcare payers. The time horizon of the model is 5 years, and costs and outcomes are discounted at an annual discount rate of 5%. - **Data Sources**: Model parameters are mainly from clinical trial data, literature reports, and data from the Australian Bureau of Statistics. - **Sensitivity Analysis**: Probabilistic sensitivity analysis and one - factor sensitivity analysis are used to evaluate the impact of model parameter uncertainty on the results. ### Results - **Primary Results**: Compared with standard care, olaparib treatment guided by BRCA testing incurs an additional cost of AU$7,841 but gains 0.06 quality - adjusted life years (QALYs). The incremental cost - effectiveness ratio (ICER) is AU$143,613/QALY, which is higher than the willingness - to - pay threshold (AU$100,000/QALY), indicating that olaparib treatment is not cost - effective at the current price. - **Sensitivity Analysis**: If the olaparib price is reduced by 30%, the ICER will drop to AU$93,646/QALY, and at this time, the treatment has a high probability (66%) of being cost - effective. ### Discussion - **Main Findings**: The study results show that although olaparib treatment can bring health benefits, it is not cost - effective at the current price. Only when the olaparib price is significantly reduced can this treatment strategy become a cost - effective option. - **Methodological Differences**: Compared with previous studies, this study more comprehensively considers the interdependence between BRCA testing and olaparib treatment and adopts a more appropriate model design. - **Limitations**: Although the study endeavors to analyze from the perspective of Australian healthcare payers, some parameter data are still from US studies. In addition, it is assumed that all patients have not received docetaxel treatment at the start of treatment, which may affect the universality of the results. ### Conclusion This is the first study to evaluate the cost - effectiveness of germline BRCA testing and olaparib treatment as an interdependent technology combination in mCRPC. The study results suggest that if the olaparib price can be significantly reduced, this treatment strategy may be cost - effective.

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer

The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers

Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial

A review of the cost-effectiveness of genetic testing for germline variants in familial cancer

Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china

Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA

Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore

Cost-Effectiveness of Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations

Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia

Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.

Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US

The Cost-Effectiveness Analysis of Maintenance Olaparib Plus Bevacizumab in Patients with Advanced Ovarian Cancer: Based on the Final Survival Results from PAOLA-1 Trial

Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis

A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.

Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study

Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis

First-line PARP inhibitors (PARPi) with androgen receptor pathway inhibitors (ARPi) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing